Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy

Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.

Abstract

Background: A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.

Investigations: Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.

Diagnosis: Progressive neurofibromatosis-type-2-related vestibular schwannomas.

Management: Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Audiometry, Pure-Tone
  • Auditory Threshold
  • Cochlear Implantation / methods*
  • Combined Modality Therapy
  • Ear Neoplasms / complications
  • Ear Neoplasms / drug therapy*
  • Ear Neoplasms / surgery*
  • Erlotinib Hydrochloride
  • Hearing Loss, Sensorineural / diagnosis
  • Hearing Loss, Sensorineural / etiology
  • Hearing Loss, Sensorineural / prevention & control*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neurofibromatosis 2 / complications
  • Neurofibromatosis 2 / drug therapy*
  • Neurofibromatosis 2 / surgery*
  • Protein Kinase Inhibitors / administration & dosage
  • Quinazolines / administration & dosage*
  • Treatment Outcome
  • Vestibular Diseases / complications
  • Vestibular Diseases / drug therapy
  • Vestibular Diseases / surgery

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride